As of November 6, 2026, vTv Therapeutics Inc. is a publicly traded company (Nasdaq: VTVT). The largest holder reporting an active stake on Schedule 13D is Samsara BioCapital, L.P., at 9.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Trails Edge Capital Partners, LP (9.9%), Raymond Debbane (9.4%), Millennium (8.7%) (Schedule 13D/A, December 9, 2025).
Is this your company?
About to sign with, pay or invest in vTv Therapeutics Inc.? See the free Snapshot first.
Free to see. No signup.
Is vTv Therapeutics Inc. a real, registered company?
- vTv Therapeutics Inc. files with the SEC under CIK 1641489 (its SEC filings).
- Its shares are listed under the ticker VTVT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in High Point, North Carolina, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under vTv Therapeutics Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Millennium (filed 2026-10-08).
Who are vTv Therapeutics Inc.'s owners and officers?
vTv Therapeutics Inc.: incorporated in Delaware; business address in High Point, North Carolina; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-08).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-03-07)
- : Executive Officer (Form D, 2024-03-07)
- : Director (Form D, 2024-03-07)
- : Director (Form D, 2024-03-07)
- : Director (Form D, 2024-03-07)
- : Director (Form D, 2024-03-07)
- : Director (Form D, 2024-03-07)
- : Executive Officer, Director (Form D, 2024-03-07)
- : Director (Form D, 2024-03-07)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-08 | Millennium Management LLC | 8.7% |
| Schedule 13G/A, 2026-07-29 | Millennium Management LLC | 6.9% |
| Schedule 13G/A, 2026-04-16 | Millennium Management LLC | 5.7% |
| Schedule 13G, 2026-03-27 | Millennium Management LLC | 5% |
| Schedule 13D/A, 2025-12-09 | Samsara Biocapital, L.P. | 9.9% |
| Schedule 13G/A, 2025-11-12 | Raymond Debbane | 9.4% |
| Schedule 13D/A, 2025-09-25 | Samsara Biocapital, L.P. | 9.9% |
| Schedule 13G, 2025-09-08 | Raymond Debbane | 9.99% |
| Schedule 13G, 2025-09-08 | Trails Edge Capital Partners, LP | 9.9% |
| Schedule 13D/A, 2025-09-03 | Samsara Biocapital, L.P. | 9.9% |
Questions about who owns vTv Therapeutics Inc.
Who owns vTv Therapeutics Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of vTv Therapeutics Inc.: Samsara Biocapital, L.P. (9.9%, Schedule 13D/A, filed 2025-12-09), Trails Edge Capital Partners, LP (9.9%, Schedule 13G, filed 2025-09-08), Raymond Debbane (9.4%, Schedule 13G/A, filed 2025-11-12) and Millennium Management LLC (8.7%, Schedule 13G/A, filed 2026-10-08).
Who are the largest shareholders of vTv Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of vTv Therapeutics Inc. on this page are Samsara Biocapital, L.P. (9.9%), Trails Edge Capital Partners, LP (9.9%) and Raymond Debbane (9.4%).
When did Samsara Biocapital, L.P. buy into vTv Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Samsara Biocapital, L.P. on this page is the Schedule 13D/A, filed 2025-09-03, reporting 9.9%; its latest, Schedule 13D/A filed 2025-12-09, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on vTv Therapeutics Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on vTv Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on vTv Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own vTv Therapeutics Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 312,784 shares, held indirectly through By Samsara Opportunity Fund, L.P. and 1 other (Form 4, 2025-09-25).
- , L.P., a 10% owner: 206,784 shares, held indirectly through By Samsara BioCapital, L.P., on a joint filing (Form 4, 2024-12-06).
- Samsara BioCapital GP, LLC, a 10% owner: 206,784 shares, held indirectly through By Samsara BioCapital, L.P., on a joint filing (Form 4, 2024-12-06).
- , a director: 135,946 shares, held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-09-05).
- , a director: 135,946 shares, held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-09-05).
Shares only: the company's cover page does not give one share count for a single class, so no percentage is worked out.
How much has vTv Therapeutics Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-03-07 | $50.96M | $50.96M |
Keep reading
More on vTv Therapeutics Inc. and the records around it.
vTv Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
- Trails Edge Capital Partners, LP also filed stake reports on 16 other companies: Avalo Therapeutics, Inc. (Oct 2026), Sol-Gel Technologies Ltd. (Oct 2026), Contineum Therapeutics, Inc. (Oct 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/vtv-therapeutics